About Horizon Therapeutics
Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. We are creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
HZT-501: Phase 3 Trials
Phase 3 trials for our lead product candidate HZT-501 are being conducted under a Special Protocol Assessment (SPA) from FDA and began in March of 2007
Latest News
03.27.07
Horizon Therapeutics Begins Patient Enrollment in Phase 3 Trials For "GI-Friendly" NSAID